TY - JOUR
T1 - Tilianin
T2 - A potential natural lead molecule for new drug design and development for the treatment of cardiovascular disorders
AU - Khattulanuar, Farrah Syazana
AU - Sekar, Mahendran
AU - Fuloria, Shivkanya
AU - Gan, Siew Hua
AU - Mat Rani, Nur Najihah Izzati
AU - Ravi, Subban
AU - Chidambaram, Kumarappan
AU - Begum, M. Yasmin
AU - Azad, Abul Kalam
AU - Jeyabalan, Srikanth
AU - Dhiravidamani, Arulmozhi
AU - Thangavelu, Lakshmi
AU - Lum, Pei Teng
AU - Subramaniyan, Vetriselvan
AU - Wu, Yuan Seng
AU - Sathasivam, Kathiresan V.
AU - Fuloria, Neeraj Kumar
N1 - Funding Information:
This study was funded by the Deanship of Scientific Research (RGP: 1/275/1442), King Khalid University, Abha 62529, Saudi Arabia.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Cardiovascular disorders (CVDs) are the leading risk factor for death worldwide, and research into the processes and treatment regimens has received a lot of attention. Tilianin is a flavonoid glycoside that can be found in a wide range of medicinal plants and is most commonly obtained from Dracocephalum moldavica. Due to its extensive range of biological actions, it has become a well-known molecule in recent years. In particular, numerous studies have shown that tilianin has cardioprotective properties against CVDs. Hence, this review summarises tilianin’s preclinical research in CVDs, as well as its mechanism of action and opportunities in future drug development. The physicochemical and drug-likeness properties, as well as the toxicity profile, were also highlighted. Tilianin can be a natural lead molecule in the therapy of CVDs such as coronary heart disease, angina pectoris, hypertension, and myocardial ischemia, according to scientific evidence. Free radical scavenging, inflammation control, mitochondrial function regulation, and related signalling pathways are all thought to play a role in tilianin’s cardioprotective actions. Finally, we discuss tilianin-derived compounds, as well as the limitations and opportunities of using tilianin as a lead molecule in drug development for CVDs. Overall, the scientific evidence presented in this review supports that tilianin and its derivatives could be used as a lead molecule in CVD drug development initiatives.
AB - Cardiovascular disorders (CVDs) are the leading risk factor for death worldwide, and research into the processes and treatment regimens has received a lot of attention. Tilianin is a flavonoid glycoside that can be found in a wide range of medicinal plants and is most commonly obtained from Dracocephalum moldavica. Due to its extensive range of biological actions, it has become a well-known molecule in recent years. In particular, numerous studies have shown that tilianin has cardioprotective properties against CVDs. Hence, this review summarises tilianin’s preclinical research in CVDs, as well as its mechanism of action and opportunities in future drug development. The physicochemical and drug-likeness properties, as well as the toxicity profile, were also highlighted. Tilianin can be a natural lead molecule in the therapy of CVDs such as coronary heart disease, angina pectoris, hypertension, and myocardial ischemia, according to scientific evidence. Free radical scavenging, inflammation control, mitochondrial function regulation, and related signalling pathways are all thought to play a role in tilianin’s cardioprotective actions. Finally, we discuss tilianin-derived compounds, as well as the limitations and opportunities of using tilianin as a lead molecule in drug development for CVDs. Overall, the scientific evidence presented in this review supports that tilianin and its derivatives could be used as a lead molecule in CVD drug development initiatives.
KW - Cardioprotection
KW - Cardiovascular disorders
KW - Drug development
KW - Drug-likeness
KW - Molecular mechanism
KW - Tilianin
UR - http://www.scopus.com/inward/record.url?scp=85123104369&partnerID=8YFLogxK
U2 - 10.3390/molecules27030673
DO - 10.3390/molecules27030673
M3 - Review Article
C2 - 35163934
AN - SCOPUS:85123104369
SN - 1420-3049
VL - 27
JO - Molecules
JF - Molecules
IS - 3
M1 - 673
ER -